Regenexx Announces Dr. Philippe Hernigou as New Medical Director of Clinical Research
Summary
Denver, CO, December 11, 2024 --( PR.com )-- Regenexx®, a leader in regenerative medicine and advanced orthobiologics, is proud to announce that Dr. Philippe Hernigou, a globally recognized expert in autologous cell therapy and musculoskeletal regeneration, has joined the company as its new Medical Director of Clinical Research.Dr. His appointment marks a significant milestone in Regenexx’s ongoing commitment to advancing clinical research and developing innovative, research-backed treatments for musculoskeletal conditions.“Dr. Hernigou’s wealth of knowledge and experience in regenerative medicine will be an invaluable asset as we continue to expand our clinical research efforts,” said Dr. Chris Centeno, co-founder and Chief Medical Officer of Regenexx. “Regenexx has consistently demonstrated its leadership not only through innovative science and pioneering advanced regenerative protocols with the goal of improving outcomes but also by expanding accessibility for countless individuals. Combining his vast clinical experience and data with our own will accelerate the progression of interventional orthopedic treatments and publications on their ability to reduce pain and improve function.”Regenexx’s leadership in the regenerative medicine space is powered by its commitment to high-quality, research-backed care, and the addition of Dr. Hernigou to the team will further strengthen its mission to help provide innovative, non-surgical solutions to patients suffering from musculoskeletal conditions.For more information on Regenexx and its clinical research programs, visit www.regenexx.com